Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients.
Alopecia areata, an autoimmune disease that causes partial or complete loss of hair on the scalp and body, currently has no FDA-approved treatments.
The trial will include 66 adult alopecia areata patients who will receive either 12 mg of CTP-543 twice-daily or 24 mg of CTP-543 once-daily for 24 weeks. The trial will measure the relative change in severity of alopecia tool, or SALT, score. Topline data from this trial is expected in the first half of 2020.
Topline data from Concert’ first open label trial, which is currently assessing 8 mg of CTP-543 twice-daily versus 16 mg of CTP-543 once-daily for 24 weeks, is expected in the fourth quarter of this year.